论文部分内容阅读
目的比较胰岛素持续皮下输注(CSⅡ)与胰岛素多次皮下注射(MSⅡ)方案治疗儿童T1DM的疗效及安全性。方法 T1DM患儿72例随机分为CSⅡ组32例和MSⅡ组40例,治疗3个月。比较治疗前后FPG、2hPG、HbA1c、24h血糖波动情况及低血糖事件发生情况。结果 (1)治疗后,两组FPG和HbA1c均较治疗前降低(P<0.05),但两组比较差异无统计学意义(P>0.05);(2)CSⅡ组24h内平均血糖波动幅度(MAGE)、全天血糖值标准差(SDBG)、日间血糖平均绝对差(MODD)均低于MSⅡ组[MAGE:(1.9±0.5)vs(2.2±0.4)mmol/L;SDBG:(2.1±0.3)vs(2.4±0.4)mmol/L;MODD:(3.3±1.4)vs(4.1±1.5)mmol/L,P<0.05];(3)CSⅡ组低血糖发生率低于MSⅡ组,但两组均无严重低血糖事件。结论 CSⅡ治疗血糖波动较大的T1DM患儿疗效和安全性均优于MSⅡ。
Objective To compare the efficacy and safety of insulin continuous subcutaneous infusion (CS Ⅱ) and insulin multiple subcutaneous injections (MS Ⅱ) in children with T1DM. Methods Totally 72 children with T1DM were randomly divided into CS Ⅱ group (32 cases) and MS Ⅱ group (40 cases) for 3 months. Before and after treatment FPG, 2hPG, HbA1c, 24h blood glucose fluctuations and hypoglycemic events. Results (1) After treatment, FPG and HbA1c in both groups were lower than before treatment (P <0.05), but there was no significant difference between the two groups (P> 0.05); (2) MAGE: (1.9 ± 0.5) vs (2.2 ± 0.4) mmol / L; SDBG: (2.1 ± SD); mean daily blood glucose level (SDBG) (3.3 ± 1.4) vs (4.1 ± 1.5) mmol / L, P <0.05]; (3) The incidence of hypoglycemia in CSⅡ group was lower than that in MSⅡ group There were no severe hypoglycemic events in the group. Conclusion The efficacy and safety of CSⅡ in patients with T1DM with large blood glucose fluctuation are superior to those of MS Ⅱ.